Dr Gael Morrow g.morrow1@rgu.ac.uk
Chancellor's Fellow
Dr Gael Morrow g.morrow1@rgu.ac.uk
Chancellor's Fellow
Traumatic injury accounts for 4.9 million deaths worldwide each year. Approximately 25% of trauma patients die within 6 h of injury from uncontrolled bleeding, termed trauma induced coagulopathy (TIC). TIC describes the overall failure of the blood clotting system to stop bleeding after injury. TIC is associated with an increased need for transfusion therapy and a 3-4 fold increased risk of death. Major trauma costs the NHS £150 million per year, with transfusion therapies accounting for approximately 12% of this cost.
Tranexamic acid (TXA) is an anti-fibrinolytic drug given to prevent bleeding, however, there is a short window of time (3h post-injury) where it can be used safely. This project will investigate changes in key molecules of the blood clotting process over time to determine why TXA becomes harmful 3h post-injury.
Type of Project | Research Grant |
---|---|
Status | Project Live |
Funder(s) | Friends of Anchor |
Value | £12,348.00 |
Project Dates | Oct 1, 2024 - Sep 30, 2025 |
How do fresh whole blood and blood component therapies containing additive solutions alter the structure and stability of a blood clot during traumatic bleeding? Dec 1, 2023 - Nov 30, 2024
In a military setting, bleeding is the primary cause of preventable death in patients suffering from polytrauma and massive haemorrhage. Access to hospital care and blood products is limited by location, logistics and personnel. Pre-hospital blood in...
Read More about How do fresh whole blood and blood component therapies containing additive solutions alter the structure and stability of a blood clot during traumatic bleeding?.
Binding affinity of different commercial FIX therapies to collagen IV Oct 1, 2023 - Nov 30, 2024
Haemophilia B is a blood clotting disorder caused by deficiency of blood coagulation Factor IX (FIX), resulting in bruising and bleeding. Haemophilia B affects 1:30,000 males in the UK and is treated by infusion of FIX concentrate to sustain normal f...
Read More about Binding affinity of different commercial FIX therapies to collagen IV.
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search